Correlation Between Crispr Therapeutics and Adaptive Biotechnologies
Can any of the company-specific risk be diversified away by investing in both Crispr Therapeutics and Adaptive Biotechnologies at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crispr Therapeutics and Adaptive Biotechnologies into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Crispr Therapeutics AG and Adaptive Biotechnologies Corp, you can compare the effects of market volatilities on Crispr Therapeutics and Adaptive Biotechnologies and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crispr Therapeutics with a short position of Adaptive Biotechnologies. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crispr Therapeutics and Adaptive Biotechnologies.
Diversification Opportunities for Crispr Therapeutics and Adaptive Biotechnologies
0.56 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Crispr and Adaptive is 0.56. Overlapping area represents the amount of risk that can be diversified away by holding Crispr Therapeutics AG and Adaptive Biotechnologies Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Adaptive Biotechnologies and Crispr Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crispr Therapeutics AG are associated (or correlated) with Adaptive Biotechnologies. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Adaptive Biotechnologies has no effect on the direction of Crispr Therapeutics i.e., Crispr Therapeutics and Adaptive Biotechnologies go up and down completely randomly.
Pair Corralation between Crispr Therapeutics and Adaptive Biotechnologies
Given the investment horizon of 90 days Crispr Therapeutics AG is expected to under-perform the Adaptive Biotechnologies. But the stock apears to be less risky and, when comparing its historical volatility, Crispr Therapeutics AG is 1.53 times less risky than Adaptive Biotechnologies. The stock trades about -0.03 of its potential returns per unit of risk. The Adaptive Biotechnologies Corp is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest 470.00 in Adaptive Biotechnologies Corp on August 27, 2024 and sell it today you would lose (1.00) from holding Adaptive Biotechnologies Corp or give up 0.21% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Crispr Therapeutics AG vs. Adaptive Biotechnologies Corp
Performance |
| Timeline |
| Crispr Therapeutics |
| Adaptive Biotechnologies |
Crispr Therapeutics and Adaptive Biotechnologies Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Crispr Therapeutics and Adaptive Biotechnologies
The main advantage of trading using opposite Crispr Therapeutics and Adaptive Biotechnologies positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crispr Therapeutics position performs unexpectedly, Adaptive Biotechnologies can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptive Biotechnologies will offset losses from the drop in Adaptive Biotechnologies' long position.| Crispr Therapeutics vs. Eliem Therapeutics | Crispr Therapeutics vs. HCW Biologics | Crispr Therapeutics vs. Scpharmaceuticals | Crispr Therapeutics vs. Milestone Pharmaceuticals |
| Adaptive Biotechnologies vs. Verve Therapeutics | Adaptive Biotechnologies vs. Beam Therapeutics | Adaptive Biotechnologies vs. Caribou Biosciences | Adaptive Biotechnologies vs. Sana Biotechnology |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Complementary Tools
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |